The latentiation process in drug design;O processo de latenciação no planejamento de fármacos

Quimica Nova

Volumn 22, Issue 1, 1999, Pages 75-84

  Chin, Chung Man ^a   Ferreira, Elizabeth Igne ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Drug design; Latentiation; Molecular modification; Prodrug design

Indexed keywords

EID: 0001912179     PISSN: 01004042     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0100-40421999000100014     Document Type: Article

References (87)

1. Korolkovas, A.; Essentials of medicinal chemistry. Wiley-Interscience; New York, 1988; 2nd ed.
2. Bundgaard, H., Ed.; Design of prodrugs, Elsevier; Amsterdam, 1985.
3. Bundgaard, H.; Drugs Fut. 1991, 16, 443.
4. Krogsgaard-Larsen, P.; Liljefors, T. e Madsen, U. Eds.; A textbook of drug design and development; Academic Publishers, Harwood, 1996. 2nd ed.
5. Meier, C. et al.; Nucleosides & Nucleotides 1995, 14, 759.
6. Rosenblum, J. S. et al.; Angew. Chem. Int. Ed. Engl. 1995, 34, 2275.
7. Blakey, D. C. et al.; Brit. J. Cancer 1995, 72, 1083.
8. Azoulay, M. et al.; Anti-Cancer Drug Design 1995, 10, 441.
9. Trinh, Q. T. et al.; Cancer Res. 1995, 55, 4808.
10. Beall, H. D.; Prankerd, R. J. e Sloan, K. B.; Drug Develop. Ind. Pharm. 1996, 22, 85.
11. Bonnaffe, D. et al.; J. Org. Chem. 1996, 61, 895.
12. McGulgan, C. et al.; Antiviral Chem. 1996, 7, 31.
13. Szczech, G. M.; Clin.Infect. Dis. 1996, 22, 355.
14. Wang, L. L. et al.; J. Med. Chem. 1996, 39, 826.
15. Hiller, S.; Science 1991, 253, 1095.
16. Wermuth, C. G.; Em Drug Design: fact or fantasy? K. R. H. Wooldridge e G. Jolles, Eds.; Academic Press, London, 1984; p.47-72.
17. Wermuth, C. G. Ed.; The practice of medicinal chemistry; Academic, London, 1996.
18. Trouet, A.; Deprez-de-Campeneere, D. e de Duve, C.; Nature (London). New Biol. 239, 110. Apud: Trouet, A.; Deprez-de-Campeneere, D.; Baurain, R. e Schneider, Y. J.; Em Drug design: fact or fantasy? K. R. H. Wooldridge e G. Jolles, Eds.; Academic Press, New York. 1984; p. 3-15.
19. Trouet, A.; Deprez-de-Campeneere, D. e de Duve, C.; Nature (London). New Biol. 239, 110. Apud: Trouet, A.; Deprez-de-Campeneere, D.; Baurain, R. e Schneider, Y. J.; Em Drug design: fact or fantasy? K. R. H. Wooldridge e G. Jolles, Eds.; Academic Press, New York. 1984; p. 3-15.
20. Trouet, A.; Deprez-de-Compeneere, D.; Baurain, R. e Schneider, Y.J.; Em Drug design: fact or fantasy? K. R. H. Wooldridge e G. Jolles, Eds.; Academic Press, New York, 1984; p. 3-15.
21. Laakso, T.; Stjarnkvist, P. e Sjoholm, I.; J. Pharm. Sci. 1987, 76, 134.
22. Trouet, A.; Masquelier, M.; Baurain, R. e Deprez-de-Campeneere, D.; Proc. Natl. Acad. Sci. USA 1982, 79, 626.
23. Duncan, R. et al.; Brit. J. Cancer 1987, 55, 165.
24. Tubaro, E. e Raffaldoni, E.; Boll. Chim. Farm. 1961, 100, 9.
25. Bundgaard, H.; Larsen, C. e Thorbek, P.; Int. J. Pharm. 1984, 18, 67.
26. Yamaoka, Y.; Roberts, R. D. e Stella, V. J.; J. Pharm. Sci. 1983, 72, 400.
27. Clerici, C. et al.; Dig. Dis. Sci. 1994, 39, 2601.
28. Bai, J. P. F.; Pharm. Res. 1995, 12, 1101.
29. Pochopin, N. L.; Charmon, W. N. e Stella, V. J.; Int. J. Pharm. 1995, 121, 157.
30. Nolen III, H.; Fedorak, R. N. e Friend, D. R.; J. Pharm. Sci. 1995, 84, 677.
31. Fredholt, K.; Møarck, N. e Begtrup, M.; Int. J. Pharm. 1995, 123, 209.
32. Patel, J. et al.; J. Pharm. Sci. 1995, 84, 174.
33. Takata, J.; Karube, Y.; Nagata, Y. e Matsushima, Y.; J. Pharm. Sci. 1995, 84, 96.
34. Elfarra, A. A. et al.; J. Pharm. Exp. Ther. 1995, 274, 1298.
35. Wilk, S.; Mizoguchi, H. e Orlowski, M.; J. Pharmacol. Exp. Ther. 1978, 206, 227.
36. Stella, V. J. e Kearney, A. S. Em Targeted drug delivery, R. L. Juliano, Ed.; Springer-Verlag, Heidelberg, 1991; p. 71-103. (Handbook of Experimental Pharmacology, v.100).
37. Takakura, Y. e Hashida, M.; Crit. Rev. Oncol. Hematol. 1994, 18, 207.
38. Jain, R. K.; Cancer Metastasis Rev. 1987, 6, 559.
39. O'Connor, S. W. e Bale, W. F.; Cancer Res. 1984, 44, 3719.
40. Matsumara, Y. e Maeda, H.; Cancer Res. 1986, 46, 6387.
41. Takakura, Y.; Fujita, T.; Hashida, M. e Sezaki, H.; Pharm. Res. 1990, 7, 339.
42. Takakura, Y.; Tabagi, A.; Hashida, M. e Sezaki, H.; Pharm. Res. 1987, 4, 293.
43. Sezaki, H. e Hashida, M.; Crit. Rev. Ther. Drug Carrier Syst. 1984, 1, 1.
44. Sezaki, H.; Takakura, Y. e Hashida, M.; Adv. Drug Delivery Rev. 1989, 3, 247.
45. Yokoyama, M. et al.; Cancer Res. 1990, 50, 1693.
46. Yokoyama, M. et al.; Cancer Res. 1991, 51, 3229.
47. Nishida, K.; Kido, M.; Sasaki, H. e Nakamura, J.; Pharm. Res. 1994, 11, 160.
48. Vitols, K. S. et al.; Cancer Res. 1995, 55, 478.
49. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. e Weber, M. J.; Proc. Natl. Acad. Sci. USA. 1980, 77, 2224.
50. Chakravarty, P. K.; Carl, P. L.; Weber, M. J. e Katzenellenbogen, J. A.; J. Med. Chem. 1983, 26, 638.
51. Singh, G. e Sharma, P. D.; Indian J. Pharm. Sci. 1994, 56, 66.
52. Klotz, U. et al.; N. Engl. J. Med, 1980, 303, 1499.
53. Korolkovas, A.; Dicionário terapêutico Guanabara 96/97; Guanabara Koogan, Rio de Janeiro, 1996.
54. Schaefer, W. Ger. (East) DD. 255,941 (C1C07C101/74), 20 Apr. 1988, Appl. 298,386,24 Dec. 1986.
55. Vilaseca, J. et al.; Gastroenterology 1990, 98, 269.
56. Insel, P. A.; Em Goodman & Gilman's. The pharmacological bases of therapeutics, J. G. Hardman, et al. Eds.;. Mc Graw Hill, New York, 1996, 9.ed.; p. 617-57.
57. Ferres, H.; Drugs Fut. 1983, 19, 499.
58. Albrecht, H. A. et al.; J. Med. Chem. 1990, 33, 77.
59. Albrecht, H. A. et al.; J. Med. Chem. 1991, 34, 2857.
60. Gall, M.; Hester, J. B. Jr.; Rudzik, A. D. e Lahti, R. A.; J. Med. Chem. 1976, 19, 1057.
61. Lahti, R. A. e Gall, M.; J. Med. Chem. 1976, 19, 1064.
62. Bodor, N.; Drug Delivery, 5, pat. 4,479,932. Apud: Brewster, M. E. e Bodor, N.; Adv. Drug Delivery Rev. 1994, 14, 177.
63. Bodor, N.; Drug Delivery, 5, pat. 4,479,932. Apud: Brewster, M. E. e Bodor, N.; Adv. Drug Delivery Rev. 1994, 14, 177.
64. Bodor, N.; Farag, H. H. e Brewster, M. E.; Science 1981, 214, 1370.
65. Brewster, M. E. e Bodor, N.; Adv. Drug Delivery Rev. 1994, 14, 177.
66. Little, R. et al.; J. Biopharm. Sci. 1990, 1, 1.
67. Driscoll, J.S. et al.; J. Med. Chem. 1996, 39, 1619.
68. Venkatragharan, V.; Shek, E.; Perchalski, R. e Bodor, N.; Pharmacologist 1986, 28, 145.
69. Bhagrath, M. et al.; Antiviral Chem. Chemother. 1991, 2, 265.
70. Deyrup, M. et al.; Antiviral Chem. Chemother. 1991, 2, 337.
71. Hasegawa, T. e Kawaguchi, T.; Clin. Pharmacokinet. 1994, 27, 331.
72. Springer, C. J. et al.; J. Med. Chem. 1995, 38, 5051.
73. Leenders, R. G. G. et al.; Bioorg. Med. Chem. Let. 1995, 5, 2975.
74. Alexander, R. P.; Bates, R. W.; Pratt, A. J. e Kraunsoe, J. A. E.; Tetrahedron 1996, 52, 5983.
75. Baxter, L. T. e Jain, R. K.; Brit. J. Cancer 1996, 73, 447.
76. Vingerhoeds, M. H. et al.; Pharm. Res. 1996, 13, 604.
77. Stella, V. J.; Charman, W. N. A. e Naringrekar, V. H.; Drugs 1985, 29, 455.
78. Stella, V. J. e Himmelstein, K. J.; Em Design of prodrugs, H. Bundgaard, Ed.; Elsevier, Amsterdam, 1985; p. 176-198.
79. Testa, B. e Caldwell, J.; Med. Res. Rev. 1996, 16, 233.
80. Korolkovas, A.; Ferreira, E. I.; Lima, J. D. e Krettli, A. U.; Chemotherapy 1978, 24, 231.
81. Ferreira, E. I. e Korolkovas, A.; Rev. Farm. Bioquím. Univ. São Paulo 1981, 17, 28.
82. Ferreira, E. I.; Cruz, M. L. e Korolkovas, A.; Starch/Stärke 1992, 44, 21-24
83. Ohara, M. T. et al.; Boll. Chim. Farm. 1995, 134, 522.
84. Cruz, M. L.; Ferreira, E. I. e Korolkovas, A.; Starch/Stärke 1997, 49, 66.
85. Chung, M. C. et al.; J. Pharm. Sci. 1997, 86, 1127.
86. Klier, A. H.; Dissertação de Mestrado - Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo 1997.
87. Silva, M.; Disserteção de Mestrado - Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo 1997.